Quick Answer
Inhibrx Biosciences, Inc. reported Long Term Debt of $100.56 million for the year ending 2025.
- This data is from Inhibrx Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2024: $0.00 | Q3 2024: $0.00 | Q1 2025: $98.65 million | Q2 2025: $99.28 million | Q3 2025: $99.92 million.
- Over the full 3 years of available data (2023 to 2025), Inhibrx Biosciences, Inc.'s Long Term Debt has declined by 51.4%.
- Historical annual values: Fiscal year 2025: $100.56 million | Fiscal year 2024: $0.00 | Fiscal year 2023: $206.97 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: